Philadelphia chromosome-positive mature B-cell (Burkitt cell) leukaemia

Br J Haematol. 2002 Aug;118(2):559-62. doi: 10.1046/j.1365-2141.2001.03598.x.

Abstract

Philadelphia chromosome-positive (Ph+) acute leukaemia usually shows lymphoblastic morphology and a B-precursor phenotype. The bone marrow aspirate of a 9-year-old boy showed a L3 blast cell morphology in 90% of cells; immunophenotyping revealed a mature B-blast population. The translocation t(9;22) (q34;q11) was seen in 45 out of 50 metaphases, and expression of the corresponding bcr1/abl fusion transcripts, but no IgH/myc co-localization or splitting of c-myc, was demonstrated. Chemotherapy according to the Berlin-Frankfurt-Munster non-Hodgkin's lymphoma (NHL-BFM 95) protocol with maintenance according to the BFM acute lymphoblastic leukaemia (ALL-BFM 90) protocol resulted in continuing complete remission of 54 months. The occurrence of Ph+ Burkitt's leukaemia might reflect multiple-step cancer development.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Burkitt Lymphoma / drug therapy
  • Burkitt Lymphoma / genetics
  • Burkitt Lymphoma / pathology*
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / pathology
  • Child
  • Fusion Proteins, bcr-abl / genetics
  • Gene Rearrangement, B-Lymphocyte, Light Chain
  • Humans
  • Immunophenotyping / methods
  • Karyotyping / methods
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Translocation, Genetic

Substances

  • Fusion Proteins, bcr-abl